Christopher Causey Sells 1,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total transaction of $440,000.00. Following the sale, the director directly owned 4,865 shares of the company’s stock, valued at $2,140,600. This represents a 17.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Christopher Causey also recently made the following trade(s):

• On Tuesday, September 2nd, Christopher Causey sold 3,000 shares of United Therapeutics stock. The shares were sold at an average price of $423.21, for a total value of $1,269,630.00.

United Therapeutics Stock Down 3.0%

Shares of UTHR stock opened at $425.42 on Friday. The business has a 50-day moving average price of $340.09 and a two-hundred day moving average price of $313.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $442.01. The firm has a market cap of $19.19 billion, a P/E ratio of 16.61, a price-to-earnings-growth ratio of 6.69 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the business posted $5.85 earnings per share. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new stake in United Therapeutics in the second quarter worth $136,453,000. Invesco Ltd. lifted its position in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. AQR Capital Management LLC boosted its stake in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares in the last quarter. Vaughan Nelson Investment Management L.P. purchased a new position in shares of United Therapeutics during the first quarter valued at about $101,354,000. Finally, Nuveen LLC bought a new position in United Therapeutics in the first quarter worth about $83,533,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on UTHR shares. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, September 4th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. HC Wainwright raised their price target on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Finally, Jefferies Financial Group lifted their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.